Veriq Limited Secures £129.2k Pre-Seed Funding to Accelerate Clinical Trials

Veriq Limited, a London based MedTech clinical trial accelerator, has successfully raised an estimated £129.2k in a pre-seed funding round. The investment brings the company to an estimated post-money valuation of £312k. The allotment date for the round was 21 December 2025, with the official filing completed on 5 March 2026.

Incorporated in September 2025, Veriq Limited was established to address significant bottlenecks in the medical technology development lifecycle. The company partners directly with MedTech developers to design and execute clinical studies. Their primary focus is on delivering faster and higher quality clinical research by enabling rapid study set-up, accelerating patient recruitment, and ensuring consistent data quality throughout the trial process.

Bringing new medical devices to market requires rigorous clinical validation, a process that is often delayed by administrative hurdles and slow patient enrollment. By streamlining these critical phases, Veriq Limited aims to reduce the time and cost associated with clinical trials, allowing developers to deploy life saving technologies more efficiently.

As a newly formed entity, Veriq Limited is currently in its earliest stages of operation. The company reports zero full time employees and has not yet disclosed revenue or profit figures, which is standard for a pre-seed startup focused on building its initial service infrastructure.

The £129.2k pre-seed round represents the first major capital injection